Oracle Investment Management, Inc. (OIM) is a fundamental research driven investment management company that is exclusively focused on the
Business Model:
Revenue: $0
Employees: 0-0
Address: 200 Greenwich Avenue
City: Greenwich
State: CT
Zip: 06830
Country: US
Oracle Investment Management, Inc. (OIM) is a fundamental research driven investment management company that is exclusively focused on the global health care and bioscience industries. The firm was founded by Larry N. Feinberg in 1993. Mr. Feinberg has been a leading investor and securities analyst in the health care industry for over 30 years. The current Health Care industry is characterized by rapid and disrupting changes driven by innovation and regulation. Besides the passage of Health Reform legislation, demand for health care is also accelerating as the population of the developed world ages. At 17% of GDP, health care spending in the United States is more than 4 times greater than the amount spent on national defense. These forces provide opportunities for both long and short investing, based on our fundamental security selection process.
Contact Phone:
+12038621660
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2019 | Concentric Analgesics | Series B | 77.1M |
8/2014 | Yield10 Bioscience | Post-IPO Equity | 25M |
11/2021 | Core Starters | Seed Round | 0 |
6/2014 | Transition Therapeutics | Post-IPO Equity | 0 |
3/2015 | Hansen Medical | Post-IPO Equity | 0 |
3/2013 | Mend | Seed Round | 1M |
12/2014 | Aspira Women&s;s Health | Post-IPO Equity | 0 |
2/2014 | Biolase | Post-IPO Equity | 0 |
10/2021 | Pyramid Biosciences | Series B | 0 |
5/2013 | Aspira Women&s;s Health | Post-IPO Equity | 13.2M |
12/2018 | Soleno Therapeutics | Post-IPO Equity | 0 |
12/2013 | Aspira Women&s;s Health | Post-IPO Equity | 0 |
11/2021 | Core Starters | Seed Round | 0 |
10/2021 | Pyramid Biosciences | Series B | 0 |
5/2019 | Concentric Analgesics | Series B | 0 |
12/2018 | Soleno Therapeutics | Post-IPO Equity | 0 |
3/2015 | Hansen Medical | Post-IPO Equity | 0 |
12/2014 | Aspira Women&s;s Health | Post-IPO Equity | 0 |
8/2014 | Yield10 Bioscience | Post-IPO Equity | 0 |
6/2014 | Transition Therapeutics | Post-IPO Equity | 0 |
2/2014 | Biolase | Post-IPO Equity | 0 |
12/2013 | Aspira Women&s;s Health | Post-IPO Equity | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|